CRIS Current Research Information System

TACCHETTI, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.095
AS - Asia 6.894
EU - Europa 4.436
AF - Africa 429
SA - Sud America 380
Continente sconosciuto - Info sul continente non disponibili 336
OC - Oceania 11
Totale 19.581
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.941
VN - Vietnam 2.110
CN - Cina 1.740
SG - Singapore 1.639
IT - Italia 1.076
GB - Regno Unito 872
SE - Svezia 514
DE - Germania 513
HK - Hong Kong 397
FR - Francia 290
IN - India 278
BR - Brasile 266
NL - Olanda 222
RU - Federazione Russa 200
KR - Corea 184
IE - Irlanda 161
CI - Costa d'Avorio 146
BD - Bangladesh 141
UA - Ucraina 131
FI - Finlandia 124
ZA - Sudafrica 97
JP - Giappone 92
TG - Togo 78
CA - Canada 74
SC - Seychelles 64
EE - Estonia 60
PH - Filippine 50
AR - Argentina 48
BG - Bulgaria 46
CH - Svizzera 45
TH - Thailandia 37
BE - Belgio 36
AT - Austria 34
JO - Giordania 33
MX - Messico 33
PL - Polonia 31
ES - Italia 27
TR - Turchia 24
TW - Taiwan 23
ID - Indonesia 19
EC - Ecuador 18
IQ - Iraq 18
IR - Iran 18
CO - Colombia 16
LB - Libano 14
NG - Nigeria 13
SA - Arabia Saudita 13
CL - Cile 12
CZ - Repubblica Ceca 11
IL - Israele 10
JM - Giamaica 10
PK - Pakistan 10
UZ - Uzbekistan 10
AU - Australia 9
GR - Grecia 9
MY - Malesia 8
VE - Venezuela 8
EG - Egitto 7
LT - Lituania 7
SV - El Salvador 7
GT - Guatemala 6
PY - Paraguay 6
RO - Romania 6
CR - Costa Rica 5
DZ - Algeria 5
PT - Portogallo 5
KE - Kenya 4
MA - Marocco 4
NP - Nepal 4
TN - Tunisia 4
TT - Trinidad e Tobago 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
HN - Honduras 3
NI - Nicaragua 3
OM - Oman 3
PE - Perù 3
AL - Albania 2
BS - Bahamas 2
CY - Cipro 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
GH - Ghana 2
HR - Croazia 2
HU - Ungheria 2
KG - Kirghizistan 2
KZ - Kazakistan 2
NO - Norvegia 2
PS - Palestinian Territory 2
RS - Serbia 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
BB - Barbados 1
BO - Bolivia 1
BY - Bielorussia 1
CW - ???statistics.table.value.countryCode.CW??? 1
GD - Grenada 1
GE - Georgia 1
KH - Cambogia 1
Totale 19.232
Salva come PNG Salva come JPEG
Città #
Singapore 1.138
Ashburn 853
Southend 713
Fairfield 587
Chandler 555
Ho Chi Minh City 474
Hanoi 425
San Jose 378
Hong Kong 374
Hefei 368
Bologna 280
Woodbridge 278
Seattle 260
Wilmington 243
Beijing 226
Ann Arbor 221
Houston 218
Cambridge 214
Dallas 190
Santa Clara 187
Dong Ket 178
Princeton 168
Seoul 163
Council Bluffs 158
Dublin 157
New York 149
Abidjan 146
Boardman 132
Los Angeles 112
Lauterbourg 107
Helsinki 94
Lomé 78
Tokyo 74
Jacksonville 73
Haiphong 70
Nanjing 70
Westminster 66
Bremen 65
Milan 65
Padova 62
São Paulo 61
Frankfurt am Main 53
Berlin 51
Buffalo 51
Da Nang 50
Jinan 49
Hyderabad 45
Sofia 45
Turin 44
Munich 43
San Diego 41
Shenyang 39
Guangzhou 37
Rome 37
Changsha 36
Bengaluru 35
Redondo Beach 35
Brussels 34
Saint Petersburg 34
Amman 33
Redwood City 33
Shanghai 33
Bern 32
Nanchang 29
Tianjin 29
Zhengzhou 29
Amsterdam 28
Chicago 28
London 26
Johannesburg 24
Hebei 22
Phoenix 22
Redmond 22
Can Tho 21
Florence 21
Ha Long 21
Vienna 21
Falkenstein 20
Lappeenranta 20
Nuremberg 20
Atlanta 19
Biên Hòa 19
Jiaxing 19
Paris 19
Washington 19
Brooklyn 18
Fabriano 18
Hangzhou 18
Hải Dương 18
Quận Bình Thạnh 18
San Francisco 18
Thái Nguyên 18
Montreal 17
Ninh Bình 17
Orem 17
Shenzhen 17
Toronto 17
Dongguan 15
Mülheim 15
Norwalk 15
Totale 12.074
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 719
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 359
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. 314
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment 272
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 256
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. 252
Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma. 251
Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma 239
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes 238
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model 238
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 237
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS 226
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma 223
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma 222
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 221
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. 221
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. 220
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. 218
Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study 213
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients 213
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 213
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 213
11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. 209
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment 206
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 205
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma 205
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma 204
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. 202
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation 202
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. 201
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 201
Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. 199
Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation. 198
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. 197
Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma 196
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 194
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. 193
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma 192
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. 188
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 188
Thalidomide maintenance in multiple myeloma: certainties and controversies. 185
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis 184
Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. 183
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 182
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma 182
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. 181
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 181
Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. 180
Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma 178
Dermoscopy of cutaneous involvement by multiple myeloma 177
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents 177
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 177
Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy 177
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 176
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients 172
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 169
Early Light Chains Removal and Albumin Levels with a Double Filter-Based Extracorporeal Treatment for Acute Myeloma Kidney 165
First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. 165
Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 164
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. 163
OAB-006: A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma 160
Maintenance therapy in newly diagnosed multiple myeloma: current recommendations. 160
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation 159
Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease. 158
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 156
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treatedwith zoledronic acid and thalidomide-dexamethasone. 156
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features 155
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 154
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. 154
Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials 153
SIRT Regulates the Molecular Interaction Between c-MYC and HIF-1α in Multiple Myeloma 147
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients 146
VarianThinker: a classification method to confidently approach the mutation heterogeneity in Multiple Myeloma 146
Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma 143
Rare, but complex chromosomal rearrangements, defined "Chromoanagenesis”, caused by single-step or stepwise catastrophic genomic events, significantly impact on Multiple Myeloma patients 142
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. 141
Neuropathy in multiple myeloma treated with thalidomide: a prospective study. 140
Role of consolidation therapy in transplant eligible multiple myeloma patients. 139
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. 137
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review 137
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 136
Imaging in multiple myeloma: How? When? 136
Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. 135
Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation 135
Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects. 131
Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients 131
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 130
Extramedullary metastatic plasmacytoma in a multiple myeloma patient 129
Interference of daratumumab and efficacy of plerixafor on haematopoietic stem cell collection in Multiple Myeloma 126
Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma 125
Case Report: Uncommon co-occurrence of different renal histopathological entities in a patient with multiple myeloma and lymphoplasmacytic lymphoma 124
Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients 124
Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma 123
The Value of 18F-FDG PET/CT after Autologous Stem Cell Transplantation (ASCT) in Patients Affected by Multiple Myeloma (MM): Experience With 77 Patients 123
Multiple myeloma: disease response assessment 113
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial 113
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study 111
T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS 101
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study 101
Bispecific Antibodies and CAR T in Multiple Myeloma: Appropriate Selection of Patients and Sequencing 98
Totale 18.304
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.002
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.002
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.510 0 75 98 123 156 77 31 114 65 165 306 300
2022/20232.251 206 349 95 350 142 199 76 120 352 76 171 115
2023/2024748 44 114 48 58 68 184 33 90 9 31 42 27
2024/20252.602 136 295 220 212 279 125 205 95 60 293 183 499
2025/20267.617 716 1.181 614 562 687 397 647 214 1.421 553 339 286
2026/2027466 204 262 0 0 0 0 0 0 0 0 0 0
Totale 19.581